Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Lly save search
Innovent Announces the Phase 3 ORIENT-16 Study Results Published in JAMA Evaluating Sintilimab in Combination with Chemotherapy for the First-Line Treatment of Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma
Published: 2023-12-06 (Crawled : 01:00) - prnewswire.com
SNY | News | $46.34 -1.45% -1.47% 1.4M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $93.9 1.45% 2.1K
|
Health Technology
| Email alert
Add to watchlist
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
| Email alert
Add to watchlist
INCY | $54.82 -0.26% -0.26% 1.4M
|
Health Technology
| Email alert
Add to watchlist
rient-16 treatment results study
FDA Roundup: December 05, 2023
Published: 2023-12-05 (Crawled : 23:00) - prnewswire.com
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
| Email alert
Add to watchlist
fda
Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
Published: 2023-12-04 (Crawled : 23:00) - prnewswire.com
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: 0.08%
H: 0.0%
C: 0.0%
VNDA | $3.96 2.86% 2.78% 610K
|
Health Technology
|
| O: 0.13%
H: 1.53%
C: 0.76%
drug food treatment pharmaceuticals application
Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
Published: 2023-12-04 (Crawled : 14:30) - biospace.com/
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: 0.0%
biopharma acquire
Jaypirca® (pirtobrutinib) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor
Published: 2023-12-01 (Crawled : 23:00) - prnewswire.com
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
| Email alert
Add to watchlist
jaypirca fda approved treatment leukemia
Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement
Published: 2023-12-01 (Crawled : 21:00) - globenewswire.com
VERV 4 d | $11.57 -3.66% -3.8% 1.2M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
| Email alert
Add to watchlist
offering therapeutics
AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO
Published: 2023-12-01 (Crawled : 17:00) - globenewswire.com
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
ACIU | $3.435 2.54% 2.47% 62K
|
Health Technology
|
| O: 2.64%
H: 0.0%
C: 0.0%
Acute Myocardial Infarction Treatment Market to Show Immense Growth at a CAGR of 7.7% During the Study Period (2019-2032), Predicts DelveInsight
Published: 2023-11-30 (Crawled : 22:00) - prnewswire.com
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
treatment show growth study market
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
Published: 2023-11-30 (Crawled : 08:00) - biospace.com/
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: -0.01%
H: 0.81%
C: -0.07%
FGEN | $0.553 -15.26% -18.01% 1.2M
|
Health Technology
|
| O: 10.37%
H: 11.13%
C: 4.23%
pharma
Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement
Published: 2023-11-29 (Crawled : 04:00) - globenewswire.com
VERV 4 d | $11.57 -3.66% -3.8% 1.2M
|
Professional, Scientific, and T...
|
| O: -7.79%
H: 13.21%
C: 5.66%
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
offering therapeutics
Metastatic Non-small Cell Lung Cancer Market Forecast Analysis and with Focus on its Immune/Molecular Biomarker Types: PD-L1, EGFR, KRAS, ALK, BRAF, MET, ROS-1, HER2, RET fusion, and NTRK1/2/3 Gene fusion | DelveInsight
Published: 2023-11-28 (Crawled : 22:00) - prnewswire.com
JNJ | News | $158.55 -0.21% 0.01% 7.2M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
SNY | News | $46.34 -1.45% -1.47% 1.4M
|
Health Technology
|
| O: -0.15%
H: 0.07%
C: -0.66%
BPMC | $73.25 0.73% 0.72% 600K
|
Health Technology
|
| O: 0.5%
H: 1.86%
C: -0.33%
lung biomarker cancer cell market
Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement
Published: 2023-11-28 (Crawled : 21:00) - globenewswire.com
VERV 4 d | $11.57 -3.66% -3.8% 1.2M
|
Professional, Scientific, and T...
|
| O: -7.79%
H: 13.21%
C: 5.66%
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
offering therapeutics
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego
Published: 2023-11-28 (Crawled : 21:00) - biospace.com/
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
ARE A | $119.71 -0.15% -0.59% 1.7M
|
Finance
|
| O: -0.19%
H: 3.05%
C: 2.77%
partnership
PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a Protein-Protein Interaction Target
Published: 2023-11-28 (Crawled : 20:00) - prnewswire.com
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
drug prism collaboration
Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer Symposium
Published: 2023-11-28 (Crawled : 15:30) - biospace.com/
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: 0.05%
H: 0.0%
C: 0.0%
LGND | $59.6 -0.45% -0.45% 160K
|
Health Technology
|
| O: 0.49%
H: 0.83%
C: -2.14%
breast symposium presentation cancer pharmaceuticals
Global Synthetic Hormones Market Analysis and Forecast, 2023-2033: Focus on Product Type, Application, Route of Administration, End User, Region, and Competitive Landscape
Published: 2023-11-25 (Crawled : 00:20) - prnewswire.com
PFE | News A | $29.09 -0.65% 0.03% 39M
|
Health Technology
| Email alert
Add to watchlist
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
| Email alert
Add to watchlist
NVS | News | $96.97 -2.04% 0.16% 2.8M
|
Health Technology
| Email alert
Add to watchlist
NVSEF | News | $97.95 2.98% 100
|
Health Technology
| Email alert
Add to watchlist
global market
Untapped Potential: Antibody Discovery Market to Surge to US$17.14 Billion by 2034 as Pharmaceutical Giants Focus on Orphan Drugs | Future Market Insights, Inc.
Published: 2023-11-22 (Crawled : 23:00) - prnewswire.com
DHR | News | $219.44 -1.21% 0.0% 2.7M
|
Health Technology
| Email alert
Add to watchlist
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
| Email alert
Add to watchlist
antibody market
Global Beta Blockers Market Set for Robust Growth with a CAGR of 5.19% and Market Value of $11.54 Billion by 2027
Published: 2023-11-22 (Crawled : 19:00) - prnewswire.com
SNY | News | $46.34 -1.45% -1.47% 1.4M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $93.9 1.45% 2.1K
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $104.35 -0.8% 0.0% 4.3M
|
Health Technology
| Email alert
Add to watchlist
XLRN | $179.68 0%
|
Health Technology
| Email alert
Add to watchlist
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
| Email alert
Add to watchlist
global set growth market
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Type 2 Diabetes in Diabetes Care
Published: 2023-11-22 (Crawled : 05:00) - prnewswire.com
SNYNF | News | $93.9 1.45% 2.1K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: -0.44%
H: 0.63%
C: -0.05%
SNY | News | $46.34 -1.45% -1.47% 1.4M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
ibi362 publication care chinese diabetes results phase 2
Aspirin Drug Market to Soar to US$4.2 Billion by 2034, Driven by Combination Aspirin's Dominance | Future Market Insights, Inc.
Published: 2023-11-21 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $93.9 1.45% 2.1K
|
Health Technology
|
| O: -0.74%
H: 0.71%
C: 0.71%
PRGO | $30.91 -1.44% 0.0% 1.1M
|
Health Technology
|
| O: 0.66%
H: 1.87%
C: 0.0%
LLY | News 4 d | $588.15 0.42% 0.09% 2M
|
Health Technology
|
| O: -0.44%
H: 0.63%
C: -0.05%
ABT | News | $104.35 -0.8% 0.0% 4.3M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
SNY | News | $46.34 -1.45% -1.47% 1.4M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: 0.0%
drug market
Gainers vs Losers
| 55% | 45% |
Top 10 Gainers
ZVSA | $2.03 3179.48% 96.95% 330K
|
CHSN | $4.89 68.63% 45.9% 5.7M
|
ANY M | $1.72 60.75% 37.79% 26M
|
Technology Services
VCXA | News 0 d | $15.88 60.57% 37.72% 82K
|
CNET | News | $1.12 60.0% 37.5% 3.8M
|
Commercial Services
MFH | $1.62 37.29% 27.16% 6.5M
|
Technology Services
AIHS | $0.4389 37.16% 27.09% 230K
|
Finance
KALA | $8.83 36.06% 26.5% 2.7M
|
Health Technology
JNVR | $1.53 29.66% 21.33% 2.8M
|
WHLR 4 | $0.3532 26.14% 20.72% 14M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.